Apolipoprotein B binding domains: Evidence that they are cell-penetrating peptides that efficiently deliver antigenic peptide for cross-presentation of cytotoxic T cells

Journal of Immunology

Volumn 186, Issue 8, 2011, Pages 5004-5011

  Sakamoto, Norihisa ^a   Rosenberg, Amy S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B ISOLEUCYLSERYLGLUTAMINYLALANYLVALYLHISTIDYLALANYLALANYLHISTIDYLALANYLGLUTAMYLISOLEUCYLASPARAGINYLGLUTAMYLALANYLGLYCYLARGININE; APOLIPOPROTEIN B SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; APOLIPOPROTEIN B SERYLVALYLLYSYLALANYLGLUTAMINYLTYROSYLLYSYLLYSYLASPARAGINYLSERYLASPARTYLLYSYLHISTIDYLGLYCYLGLYCYLGLYCYLARGINYLLEUCYLMETHIONYLARGINYLLYSYLARGINYLGLYCYLLEUCYLLYSINE; APOLIPOPROTEIN B100; CELL PENETRATING PEPTIDE; CPG OLIGODEOXYNUCLEOTIDE; HYBRID PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PEPTIDE VACCINE; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CULTURE; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IN VITRO STUDY; INTERNALIZATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; VACCINATION;

ANIMALS; ANTIGENS; ANTIGENS, CD11C; APOLIPOPROTEIN B-100; BINDING SITES; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; OVALBUMIN; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEOGLYCANS; RECEPTORS, LDL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79954990703     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003557     Document Type: Article

References (52)

1. Frostegård, J., A. Hamsten, M. Gidlund, and J. Nilsson. 1990. Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. J. Lipid Res. 31:37-44. (Pubitemid 20038145)
2. Hisamatsu-Sakamoto, M., N. Sakamoto, and A. S. Rosenberg. 2008. Embryonic stem cells cultured in serum-free medium acquire bovine apolipoprotein B-100 from feeder cell layers and serum replacement medium. Stem Cells 26:72-78.
3. Hevonoja, T., M. O. Pentikäinen, M. T. Hyvönen, P. T. Kovanen, and M. Ala-Korpela. 2000. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta 1488:189-210.
4. Segrest, J. P., M. K. Jones, H. De Loof, and N. Dashti. 2001. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42:1346-1367. (Pubitemid 34007665)
5. Gustafsson, M., and J. Borén. 2004. Mechanism of lipoprotein retention by the extracellular matrix. Curr. Opin. Lipidol. 15:505-514. (Pubitemid 39336577)
6. Chung, N. S., and K. M. Wasan. 2004. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 56:1315-1334. (Pubitemid 38510476)
7. Basu, S. K., J. L. Goldstein, and M. S. Brown. 1978. Characterization of the low density lipoprotein receptor in membranes prepared from human fibroblasts. J. Biol. Chem. 253:3852-3856. (Pubitemid 8361590)
8. Innerarity, T. L., K. H. Weisgraber, K. S. Arnold, R. W. Mahley, R. M. Krauss, G. L. Vega, and S. M. Grundy. 1987. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc. Natl. Acad. Sci. USA 84:6919-6923. (Pubitemid 18025501)
9. Bennett, M. W., and J. P. Caulfield. 1991. Specific binding of human low-density lipoprotein to the surface of schistosomula of Schistosoma mansoni and ingestion by the parasite. Am. J. Pathol. 138:1173-1182.
10. Stephan, Z. F., and E. C. Yurachek. 1993. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J. Lipid Res. 34:325-330. (Pubitemid 23067537)
11. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6:715-726. (Pubitemid 27305734)
12. Sakamoto, N., K. Tsuji, L. M. Muul, A. M. Lawler, E. F. Petricoin, F. Candotti, J. A. Metcalf, J. A. Tavel, H. C. Lane, W. J. Urba, et al. 2007. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 110:501-508. (Pubitemid 47105387)
13. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702.
14. Maczek, C., H. Recheis, G. Böck, T. Stulnig, G. Jürgens, and G. Wick. 1996. Comparison of low density lipoprotein uptake by different human lymphocyte subsets: a new method using double-fluorescence staining. J. Lipid Res. 37:1363-1371. (Pubitemid 26239091)
15. Raungaard, B., J. U. Brorholt-Petersen, H. K. Jensen, and O. Faergeman. 2000. Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia. J. Clin. Pharmacol. 40:421-429.
16. Løhne, K., P. Urdal, T. P. Leren, S. Tonstad, and L. Ose. 1995. Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells. Cytometry 20:290-295.
17. Suzuki, K., M. Hara, A. Kitani, M. Harigai, K. Norioka, K. Kondo, F. Hirata, N. Sakata, M. Kawakami, M. Kawagoe, and H. Nakamura. 1990. Augmentation of LDL receptor activities on lymphocytes by interleukin-2 and anti-CD3 antibody: a flow cytometric analysis. Biochim. Biophys. Acta 1042:352-358. (Pubitemid 20068938)
18. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, et al. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849-1860. (Pubitemid 24328575)
19. Wilson, N. S., D. El-Sukkari, G. T. Belz, C. M. Smith, R. J. Steptoe, W. R. Heath, K. Shortman, and J. A. Villadangos. 2003. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102:2187-2194. (Pubitemid 37122397)
20. Allan, L. L., K. Hoefl, D. J. Zheng, B. K. Chung, F. K. Kozak, R. Tan, and P. van den Elzen. 2009. Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. Blood 114:2411-2416.
21. van den Elzen, P., S. Garg, L. León, M. Brigl, E. A. Leadbetter, J. E. Gumperz, C. C. Dascher, T. Y. Cheng, F. M. Sacks, P. A. Illarionov, et al. 2005. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437:906-910. (Pubitemid 41486768)
22. Barral, D. C., and M. B. Brenner. 2007. CD1 antigen presentation: how it works. Nat. Rev. Immunol. 7:929-941. (Pubitemid 350166056)
23. Olsson, U., G. Camejo, E. Hurt-Camejo, K. Elfsber, O. Wiklund, and G. Bondjers. 1997. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Arterioscler. Thromb. Vasc. Biol. 17:149-155. (Pubitemid 27057337)
24. Cao, X., W. Zhang, L. He, Z. Xie, S. Ma, Q. Tao, Y. Yu, H. Hamada, and J. Wang. 1998. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161:6238-6244. (Pubitemid 28535997)
25. Yachi, P. P., C. Lotz, J. Ampudia, and N. R. Gascoigne. 2007. T cell activation enhancement by endogenous pMHC acts for both weak and strong agonists but varies with differentiation state. J. Exp. Med. 204:2747-2757. (Pubitemid 350044796)
26. + dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl. Acad. Sci. USA 103:10729-10734. (Pubitemid 44078044)
27. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H. W. Lee, C. G. Park, et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315:107-111. (Pubitemid 46196991)
28. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:1685-1696.
29. Burgdorf, S., C. Schölz, A. Kautz, R. Tampé, and C. Kurts. 2008. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 9:558-566. (Pubitemid 351560525)
30. Vyas, J. M., A. G. Van der Veen, and H. L. Ploegh. 2008. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8:607-618.
31. Li, S., C. Shimono, N. Norioka, I. Nakano, T. Okubo, Y. Yagi, M. Hayashi, Y. Sato, H. Fujisaki, S. Hattori, et al. 2010. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J. Biol. Chem. 285:36645-36655.
32. Goldberger, O., I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach. 2008. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res. 68:3450-3457.
33. Olofsson, S. O., and J. Borèn. 2005. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J. Intern. Med. 258:395-410. (Pubitemid 41546555)
34. Fonseca, S. B., M. P. Pereira, and S. O. Kelley. 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61:953-964.
35. Brooks, N. A., D. S. Pouniotis, C. K. Tang, V. Apostolopoulos, and G. A. Pietersz. 2010. Cell-penetrating peptides: application in vaccine delivery. Biochim. Biophys. Acta 1805:25-34.
36. Sheng, J., G. Oyler, B. Zhou, K. Janda, and C. B. Shoemaker. 2009. Identification and characterization of a novel cell-penetrating peptide. Biochem. Biophys. Res. Commun. 382:236-240.
37. Poon, G. M., and J. Gariépy. 2007. Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem. Soc. Trans. 35 (Pt. 4):788-793. (Pubitemid 47310369)
38. Jiao, C. Y., D. Delaroche, F. Burlina, I. D. Alves, G. Chassaing, and S. Sagan. 2009. Translocation and endocytosis for cell-penetrating peptide internalization. J. Biol. Chem. 284:33957-33965.
39. Turnbull, J., A. Powell, and S. Guimond. 2001. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 11:75-82. (Pubitemid 32144754)
40. Gigli, M., A. Consonni, G. Ghiselli, V. Rizzo, A. Naggi, and G. Torri. 1992. Heparin binding to human plasma low-density lipoproteins: dependence on heparin sulfation degree and chain length. Biochemistry 31:5996-6003.
41. Weisgraber, K. H., and S. C. Rall, Jr. 1987. Human apolipoprotein B-100 heparin-binding sites. J. Biol. Chem. 262:11097-11103. (Pubitemid 17122864)
42. Tyagi, M., M. Rusnati, M. Presta, and M. Giacca. 2001. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261.
43. Console, S., C. Marty, C. García-Echeverría, R. Schwendener, and K. Ballmer-Hofer. 2003. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278:35109-35114. (Pubitemid 37102274)
44. Pujals, S., J. Fernández-Carneado, C. López-Iglesias, M. J. Kogan, and E. Giralt. 2006. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta 1758:264-279. (Pubitemid 44282975)
45. Leifert, J. A., and J. L. Whitton. 2003. "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms. Mol. Ther. 8:13-20. (Pubitemid 36939292)
46. Spencer, B. J., and I. M. Verma. 2007. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl. Acad. Sci. USA 104:7594-7599. (Pubitemid 47185951)
47. Kurotaki, T., Y. Tamura, G. Ueda, J. Oura, G. Kutomi, Y. Hirohashi, H. Sahara, T. Torigoe, H. Hiratsuka, H. Sunakawa, et al. 2007. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J. Immunol. 179:1803-1813.
48. Grommé, M., F. G. Uytdehaag, H. Janssen, J. Calafat, R. S. van Binnendijk, M. J. Kenter, A. Tulp, D. Verwoerd, and J. Neefjes. 1999. Recycling MHC class I molecules and endosomal peptide loading. Proc. Natl. Acad. Sci. USA 96:10326-10331. (Pubitemid 29422557)
49. Degl'Innocenti, E., M. Grioni, A. Boni, A. Camporeale, M. T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N. M. Greenberg, and M. Bellone. 2005. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35:66-75. (Pubitemid 40123853)
50. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68:5439-5449.
51. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148. (Pubitemid 39094044)
52. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998. (Pubitemid 35363648)